搜尋結果
Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes,[12][13][14][15] particularly in people who are overweight.[13] It is also used in the treatment of polycystic ovary syndrome.[14] It is sometimes used as an off-label adjunct to lessen the risk of metabolic ...
The 2022 ADA standards of medical care in diabetes include SGLT2 inhibitors as a first line pharmacological therapy for type 2 diabetes (usually together with metformin), specifically in patients with chronic kidney disease, cardiovascular disease or heart failure.
Some DPP-4 inhibitor drugs have received approval from the FDA to be used with metformin concomitantly with additive effect to increase the level of glucagon-like peptide 1 (GLP-1) which also decreases hepatic glucose production.
其他人也問了
What is metformin used for?
What is Vildagliptin/metformin?
What is sitagliptin/metformin used for?
How effective is metformin for type 2 diabetes?
Alpha-glucosidase inhibitor. Alpha-glucosidase inhibitors ( AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar ). Carbohydrates are normally converted into simple sugars ( monosaccharides) by alpha-glucosidase enzymes present on cells lining ...
Metformin is a first-line medication used for treatment of type 2 diabetes. It is generally prescribed at initial diagnosis in conjunction with exercise and weight loss, as opposed to the past, where it was prescribed after diet and exercise had failed.
Sitagliptin/metformin, sold under the brand name Janumet among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It may be used in those whose blood sugar is not controlled with metformin and a sulfonylurea .
Vildagliptin/metformin, sold under the brand name Eucreas among others, is a fixed-dose combination anti-diabetic medication for the treatment of type 2 diabetes. It was approved for use in the European Union in November 2007, and the approval was updated in